David Turkaly
Stock Analyst at Citizens
(2.29)
# 2,761
Out of 5,090 analysts
143
Total ratings
43.51%
Success rate
-2.74%
Average return
Main Sectors:
Stocks Rated by David Turkaly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TELA TELA Bio | Maintains: Market Outperform | $7 → $5 | $1.12 | +348.43% | 7 | Nov 14, 2025 | |
| APYX Apyx Medical | Upgrades: Market Outperform | $8 | $4.06 | +97.29% | 6 | Nov 12, 2025 | |
| AXGN Axogen | Maintains: Market Outperform | $26 → $34 | $32.82 | +3.60% | 8 | Oct 30, 2025 | |
| KIDS OrthoPediatrics | Maintains: Market Outperform | $35 → $25 | $18.16 | +37.67% | 12 | Oct 10, 2025 | |
| LNTH Lantheus Holdings | Maintains: Market Outperform | $112 → $73 | $62.12 | +17.51% | 9 | Aug 7, 2025 | |
| OFIX Orthofix Medical | Reiterates: Market Perform | n/a | $15.85 | - | 2 | Jun 6, 2025 | |
| GMED Globus Medical | Reiterates: Market Perform | n/a | $88.74 | - | 3 | May 27, 2025 | |
| HAE Haemonetics | Reiterates: Market Outperform | $100 | $83.81 | +19.32% | 12 | May 20, 2025 | |
| STE STERIS | Maintains: Market Outperform | $265 → $280 | $261.02 | +7.27% | 18 | May 16, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Market Outperform | $35 → $25 | $13.55 | +84.46% | 15 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $62 → $55 | $27.96 | +96.71% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $140 → $125 | $93.16 | +34.18% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $400 → $500 | $512.55 | -2.45% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $364.35 | - | 3 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $118.86 | - | 15 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $19.33 | +65.55% | 7 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $16 | $7.76 | +106.19% | 1 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $3 | $1.47 | +104.78% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $8.59 | -41.79% | 1 | Oct 6, 2017 |
TELA Bio
Nov 14, 2025
Maintains: Market Outperform
Price Target: $7 → $5
Current: $1.12
Upside: +348.43%
Apyx Medical
Nov 12, 2025
Upgrades: Market Outperform
Price Target: $8
Current: $4.06
Upside: +97.29%
Axogen
Oct 30, 2025
Maintains: Market Outperform
Price Target: $26 → $34
Current: $32.82
Upside: +3.60%
OrthoPediatrics
Oct 10, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $18.16
Upside: +37.67%
Lantheus Holdings
Aug 7, 2025
Maintains: Market Outperform
Price Target: $112 → $73
Current: $62.12
Upside: +17.51%
Orthofix Medical
Jun 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $15.85
Upside: -
Globus Medical
May 27, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $88.74
Upside: -
Haemonetics
May 20, 2025
Reiterates: Market Outperform
Price Target: $100
Current: $83.81
Upside: +19.32%
STERIS
May 16, 2025
Maintains: Market Outperform
Price Target: $265 → $280
Current: $261.02
Upside: +7.27%
Integra LifeSciences Holdings
May 9, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $13.55
Upside: +84.46%
May 9, 2025
Maintains: Market Outperform
Price Target: $62 → $55
Current: $27.96
Upside: +96.71%
May 7, 2025
Maintains: Market Outperform
Price Target: $140 → $125
Current: $93.16
Upside: +34.18%
May 5, 2025
Maintains: Market Outperform
Price Target: $400 → $500
Current: $512.55
Upside: -2.45%
May 5, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $364.35
Upside: -
Apr 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $118.86
Upside: -
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $19.33
Upside: +65.55%
Jan 29, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $7.76
Upside: +106.19%
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $1.47
Upside: +104.78%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $8.59
Upside: -41.79%